Certara Products - Simcyp Archives | Page 7 of 22 | Certara

Case Study

Galderma Achieves FDA Approval of AKLIEF® (trifarotene)

In October 2019, Galderma announced that the U.S. FDA approved AKLIEF® (trifarotene) Cream, 0.005% for the…

CertaraNovember 9, 2020

Publication

Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics

CertaraOctober 30, 2020

Video

PBPK modeling supports approval of breakthrough cancer drug

Pharmacyclics’ (now AbbVie) Imbruvica (ibrutinib) is an anticancer drug targeting B-cell malignancies. Leveraging the US…

CertaraOctober 23, 2020

Brochure

Simcyp Drug Labels

CertaraOctober 23, 2020

Brochure

Simcyp PBPK Consulting Services

CertaraOctober 23, 2020

Publication

Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy

Model-informed precision dosing (MIPD) has become synonymous with modern approaches for individualizing drug therapy, in…

CertaraOctober 12, 2020

On-Demand Webinar

Intro to Smart In Silico Tools to Aid in Translating In Vitro & In Vivo Studies

Safety issues account for about a quarter of the attrition in drug projects, and can…

CertaraOctober 5, 2020

Fact Sheet

Secondary Intelligence

Predicts off-target risks, streamlining secondary pharmacology analysis for safer drug development.

CertaraSeptember 4, 2020

Publication

VIVD: Virtual in vitro distribution model for the mechanistic prediction of intracellular concentrations of chemicals in in vitro toxicity assays

CertaraJune 28, 2020

On-Demand Webinar

Simcyp: 20 Years of Innovation

CertaraJune 27, 2020

© 2025 Certara. All Rights Reserved. | Privacy policy